Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658157 | 1.00 | TBXAS1 (0.46) | TBXAS1GPR84RNPEPFFAR1DDAH1 | |
| SCHEMBL27413119 | 1.00 | TBXAS1 (0.46) | TBXAS1GPR84RNPEPFFAR1DDAH1 | |
| SCHEMBL1034278 | 1.00 | TBXAS1 (0.46) | TBXAS1GPR84RNPEPFFAR1DDAH1 | |
| SCHEMBL11753554 | 1.00 | TBXAS1 (0.46) | TBXAS1GPR84RNPEPFFAR1DDAH1 | |
| SCHEMBL2207820 | 1.00 | TBXAS1 (0.46) | TBXAS1GPR84RNPEPFFAR1DDAH1 | |
| SCHEMBL9679760 | 0.98 | TBXAS1 (0.45) | TBXAS1GPR84RNPEPFFAR1DDAH1 | |
| Hydrochloric Acid SCHEMBL11771270 | 0.98 | TBXAS1 (0.47) | TBXAS1GPR84RNPEPFFAR1DDAH1 | |
| SCHEMBL11693016 | 0.98 | TBXAS1 (0.43) | TBXAS1GPR84RNPEPFFAR1DDAH1 | |
| SCHEMBL1706453 | 0.90 | — | — | |
| SCHEMBL7753637 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023071328-A1 | METHOD FOR SYNTHESIZING 8-AMINO-1-{[2-(TRIMETHYLSILYL)ETHOXY]METHOXY}OCTANE-3-ONE | 苏州富士莱医药股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-115716817-A | Preparation method of 6,8-cyclotrithiooctanoic acid | 国药集团威奇达药业有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-115093392-A | Preparation method of R-lipoic acid | 苏州富士莱医药股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-113185494-B | Preparation method of R-lipoic acid | 苏州富士莱医药股份有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-113429386-B | Synthetic method of R-lipoic acid | 苏州富士莱医药股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113717210-B | Synthesis method of 8-amino-1- { [2- (trimethylsilyl) ethoxy ] methoxy } octane-3-one | 苏州富士莱医药股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-113735895-A | Preparation method of lipoic acid intermediate | 苏州富士莱医药股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-113717210-A | Synthesis method of 8-amino-1- { [2- (trimethylsilyl) ethoxy ] methoxy } octane-3-one | 苏州富士莱医药股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113429386-A | Synthetic method of R-lipoic acid | 苏州富士莱医药股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-109790111-B | Method for producing dihydrolipoic acid | 澳泽化学特罗斯特贝格有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-113185494-A | Preparation method of R-lipoic acid | 苏州富士莱医药股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20190276396-A1 | PROCESS FOR THE PRODUCTION OF DIHYDROLIPOIC ACID | ALZCHEM TROSTBERG GMBH (DE) | 2019-09-12 | — | — | US | disclosed |
| US-20070015926-A1 | Method of preparing R-(+)-alpha-lipoic acid and its salt | NANJING RALLY BIOCHEMICAL INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276396-A1 | PROCESS FOR THE PRODUCTION OF DIHYDROLIPOIC ACID | LIPA, COASY, FDFT1 | TBXAS1 580/4885GPR84 2462/4885RNPEP 1151/4885 |
| US-20070015926-A1 | Method of preparing R-(+)-alpha-lipoic acid and its salt | RALA, LIPA, DHCR7 | TBXAS1 3498/4885GPR84 4677/4885RNPEP 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.